Synapse - Paul Hamlin

Results (293)

Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: A single-center experience

Journal Article

Pak, T. K.; Dixon, B. N.; Buege, M. J.; Dao, P. H.; Leary, M. H.; Jarrett, J. C.; Duggan, T. A.; Caron, P.; Falchi, L.; Hamlin, P.; more...
Leukemia and Lymphoma (2022)

Fulltext@MSK | Save

Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma

Journal Article

Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
Blood Cancer Journal (2022)

Fulltext@MSK | Save

Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring

Journal Article

Stewart, C. M.; Michaud, L.; Whiting, K.; Nakajima, R.; Nichols, C.; De Frank, S.; Hamlin, P. A. Jr; Matasar, M. J.; Gerecitano, J. F.; Drullinsky, P.; more...
Clinical Cancer Research (2022)

Fulltext@MSK | Save

Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience

Meeting Abstract

Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
Blood (2021)

Fulltext@MSK | Save

Phase 2a study of the dual SYK/JAK inhibitor cerdulatinib (ALXN2075) as monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma

Meeting Abstract

Horwitz, S. M.; Feldman, T. A.; Ye, J. C.; Khodadoust, M. S.; Munoz, J.; Hamlin, P. A.; Kim, Y. H.; Wilcox, R. A.; Patel, M. R.; Coffey, G. P.; more...
Blood (2021)

Fulltext@MSK | Save

Phase 2a study of the dual SYK/JAK inhibitor cerdulatinib (ALXN2075) as monotherapy or in combination with rituximab in patients with relapsed/refractory follicular lymphoma

Meeting Abstract

Hamlin, P. A.; Patel, M. R.; Stevens, D.; Hess, B. T.; Munoz, J.; Feldman, T. A.; Smith, S. M.; Coffey, G. P.; Osman, M.; Holland, J. S.; more...
Blood (2021)

Fulltext@MSK | Save

Clinical outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg type treated in the rituximab era: Long-term follow-up of a single-center experience

Meeting Abstract

Falchi, L.; Qiu, A.; Ewalt, M. D.; Batlevi, C. L.; Caron, P. C.; Hamlin, P. A.; Hamilton, A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
Blood (2021)

Fulltext@MSK | Save

Impact of choice of platinum-based salvage therapy on CNS relapse in patients with relapsed or refractory diffuse large B-cell lymphoma

Meeting Abstract

Buege, M. J.; Dao, P.; Dematteo, R. G.; LeVoir, A.; Pak, T.; Batlevi, C. L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; more...
Blood (2021)

Fulltext@MSK | Save

Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Journal Article

Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: Is 4 Gy suitable for curable patients?

Journal Article

Imber, B. S.; Chau, K. W.; Lee, J.; Lee, J.; Casey, D. L.; Yang, J. C.; Wijentunga, N. A.; Shepherd, A.; Hajj, C.; Qi, S.; more...
Blood Advances (2021)

Fulltext@MSK | Save